AdultPediatricDosage Forms & Strengths tablet 500mg tablet, enteric coated (delayed release) 500mg Ulcerative Colitis Mild to moderate cases, adjunctive therapy in severe cases, and prolongation of remission 3-4 g/day PO divided TID after meals; may start 1-2 g Day; >4g/day can increase risk of toxicity Maintenance: 2 g/day in divided doses at <8 hr intervals when endoscopic exam confirms improvement Dosing modifications Reduce dose by 50% and gradually increase to desired dose over several days; stop therapy for 5-7 days if GI intolerance persists and reintroduce at lower daily dose Rheumatoid Arthritis Indicated in inadequate response or intolerance to salicylates or other NSAIDs Delayed release: 0.5-1 g/day PO divided BID; increase weekly to maintenance dose of 2 g/day PO divided BID; if response inadequate, may increase to 3 g/day after administering for 12 weeks Crohn Disease (Off-label) 3-6 g/day PO in divided doses for up to 16 wks Administration Take after meals Administer in equally divided dosesDosage Forms & Strengths tablet 500mg tablet, enteric coated (delayed release) 500 mg Ulcerative Colitis Mild to moderate cases, adjunctive therapy in severe cases, and prolongation of remission <6 years old: Safety and efficacy not established 6 years or older Initial: 40-60 mg/kg/day PO divided q4-8hr after meals Maintenance: 30 mg/kg/day PO divided q6hr after meals Juvenile Rheumatoid Arthritis Polyarticular course with inadequate response to salicylates or other NSAIDs <6 years old: Safety and efficacy not established 6 years or older: Gradually titrate at weekly intervals up to 30-50 mg/kg/day PO divided BID after meals; not to exceed 2 g/day Interaction CheckerEnter a drug name and sulfasalazineNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (19)axicabtagene ciloleucelsulfasalazine, axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.axicabtagene ciloleucel, sulfasalazine. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.brexucabtagene autoleucelsulfasalazine, brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.brexucabtagene autoleucel, sulfasalazine. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.ciltacabtagene autoleucelsulfasalazine, ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.ciltacabtagene autoleucel, sulfasalazine. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.deferipronedeferiprone, sulfasalazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis; if an alternative is not possible, monitor absolute neutrophil count more frequently.idecabtagene vicleucelsulfasalazine, idecabtagene vicleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.idecabtagene vicleucel, sulfasalazine. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.ketorolacsulfasalazine, ketorolac. Either increases toxicity of the other by pharmacodynamic synergism. Contraindicated.ketorolac intranasalsulfasalazine, ketorolac intranasal. Either increases toxicity of the other by pharmacodynamic synergism. Contraindicated.lasmiditanlasmiditan increases levels of sulfasalazine by Other (see comment). Avoid or Use Alternate Drug. Comment: Lasmiditan inhibits BCRP in vitro. Avoid coadministration of lasmiditan with BCRP substrates.leniolisibleniolisib will increase the level or effect of sulfasalazine by Other (see comment). Avoid or Use Alternate Drug. Leniolisib, a BCRP inhibitor, may increase systemic exposure of BCRP substrateslisocabtagene maraleucelsulfasalazine, lisocabtagene maraleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.lisocabtagene maraleucel, sulfasalazine. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.measles, mumps, rubella and varicella vaccine, livesulfasalazine, measles, mumps, rubella and varicella vaccine, live. Mechanism: unspecified interaction mechanism. Avoid or Use Alternate Drug. Risk of Reye's Syndrome with combination; avoid salicylate use for 6 wks after vaccination.methotrexatesulfasalazine increases levels of methotrexate by decreasing renal clearance. Avoid or Use Alternate Drug.pemetrexedsulfasalazine increases levels of pemetrexed by unspecified interaction mechanism. Avoid or Use Alternate Drug. Interrupt dosing in all patients taking NSAIDs with long elimination half-lives for at least 5d before, the day of, and 2d following pemetrexed administration. If coadministration of an NSAID is necessary, closely monitor patients for toxicity, especially myelosuppression, renal toxicity, and GI toxicity.pexidartinibsulfasalazine and pexidartinib both increase Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity.pretomanidsulfasalazine, pretomanid. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid.ropeginterferon alfa 2bropeginterferon alfa 2b, sulfasalazine. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression.tisagenlecleucelsulfasalazine, tisagenlecleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.tisagenlecleucel, sulfasalazine. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.varicella virus vaccine livesulfasalazine, varicella virus vaccine live. Mechanism: unspecified interaction mechanism. Avoid or Use Alternate Drug. Risk of Reye's Syndrome with combination; avoid salicylate use for 6 wks after vaccination.zavegepant intranasalsulfasalazine will increase the level or effect of zavegepant intranasal by Other (see comment). Avoid or Use Alternate Drug. NTCP inhibitors may result in a significant increase in systemic exposure of zavegepant (a NTCP substrate).Monitor Closely (219)acalabrutinibacalabrutinib increases levels of sulfasalazine by Other (see comment). Use Caution/Monitor. Comment: Acalabrutinib may increase exposure to coadministered BCRP substrates by inhibition of intestinal BCRP.acalabrutinib, sulfasalazine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may increase risk of myelosuppressive effects.acebutololacebutolol and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of acebutolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.aceclofenacaceclofenac and sulfasalazine both increase anticoagulation. Use Caution/Monitor.aceclofenac and sulfasalazine both increase serum potassium. Use Caution/Monitor.acemetacinacemetacin and sulfasalazine both increase anticoagulation. Use Caution/Monitor.acemetacin and sulfasalazine both increase serum potassium. Use Caution/Monitor.acetazolamideacetazolamide, sulfasalazine. Either increases levels of the other by Other (see comment). Use Caution/Monitor. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels. CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.acetazolamide, sulfasalazine. Mechanism: passive renal tubular reabsorption due to increased pH. Use Caution/Monitor. Salicylate levels increased at moderate doses; risk of CNS toxicity. Salicylate levels decreased at large doses (d/t increased renal excretion of unchanged salicylic acid).agrimonysulfasalazine and agrimony both increase anticoagulation. Use Caution/Monitor.albuterolsulfasalazine increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.alfalfasulfasalazine and alfalfa both increase anticoagulation. Use Caution/Monitor.alfuzosinsulfasalazine decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.American ginsengsulfasalazine and American ginseng both increase anticoagulation. Use Caution/Monitor.amilorideamiloride and sulfasalazine both increase serum potassium. Modify Therapy/Monitor Closely.amoxicillinamoxicillin, sulfasalazine. Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.amoxicillin, sulfasalazine. Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.ampicillinampicillin, sulfasalazine. Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.ampicillin, sulfasalazine. Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.antithrombin alfaantithrombin alfa and sulfasalazine both increase anticoagulation. Modify Therapy/Monitor Closely.antithrombin IIIantithrombin III and sulfasalazine both increase anticoagulation. Modify Therapy/Monitor Closely.apalutamideapalutamide will decrease the level or effect of sulfasalazine by increasing elimination. Use Caution/Monitor. Apalutamide weakly induces BCRP and may decrease systemic exposure of drugs that are BCRP substrates.arformoterolsulfasalazine increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.argatrobanargatroban and sulfasalazine both increase anticoagulation. Modify Therapy/Monitor Closely.asenapinesulfasalazine decreases effects of asenapine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.aspirinaspirin and sulfasalazine both increase anticoagulation. Use Caution/Monitor.aspirin and sulfasalazine both increase serum potassium. Use Caution/Monitor.aspirin rectalaspirin rectal and sulfasalazine both increase anticoagulation. Use Caution/Monitor.aspirin rectal and sulfasalazine both increase serum potassium. Use Caution/Monitor.aspirin/citric acid/sodium bicarbonateaspirin/citric acid/sodium bicarbonate and sulfasalazine both increase anticoagulation. Use Caution/Monitor.aspirin/citric acid/sodium bicarbonate and sulfasalazine both increase serum potassium. Use Caution/Monitor.atenololatenolol and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of atenolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.azilsartansulfasalazine, azilsartan. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.sulfasalazine decreases effects of azilsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.bemiparinbemiparin and sulfasalazine both increase anticoagulation. Modify Therapy/Monitor Closely.benazeprilsulfasalazine decreases effects of benazepril by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Potential for dangerous interaction. Use with caution and monitor closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.benazepril, sulfasalazine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.bendroflumethiazidesulfasalazine increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.betaxololbetaxolol and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of betaxolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.bisoprololbisoprolol and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of bisoprolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.bivalirudinbivalirudin and sulfasalazine both increase anticoagulation. Modify Therapy/Monitor Closely.brinzolamidebrinzolamide, sulfasalazine. Either increases levels of the other by Other (see comment). Use Caution/Monitor. Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels. CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.budesonidesulfasalazine, budesonide. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.bumetanidesulfasalazine increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.sulfasalazine decreases effects of bumetanide by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.bupivacaine implantsulfasalazine, bupivacaine implant. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Local anesthetics may increase the risk of developing methemoglobinemia when concurrently exposed to drugs that also cause methemoglobinemia.candesartancandesartan and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of candesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.candesartan, sulfasalazine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.captoprilsulfasalazine decreases effects of captopril by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.captopril, sulfasalazine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.carbenoxolonesulfasalazine increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.carvedilolcarvedilol and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.celecoxibcelecoxib and sulfasalazine both increase anticoagulation. Use Caution/Monitor.celecoxib and sulfasalazine both increase serum potassium. Use Caution/Monitor.celiprololceliprolol and sulfasalazine both increase serum potassium. Use Caution/Monitor.sulfasalazine decreases effects of celiprolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use. NSAIDs decrease prostaglandin synthesis.chlorothiazidesulfasalazine increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpropamidesulfasalazine increases effects of chlorpropamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.chlorthalidonesulfasalazine increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.choline magnesium trisalicylatecholine magnesium trisalicylate and sulfasalazine both increase anticoagulation. Use Caution/Monitor.choline magnesium trisalicylate and sulfasalazine both increase serum potassium. Use Caution/Monitor.cinnamonsulfasalazine and cinnamon both increase anticoagulation. Use Caution/Monitor.clomipramineclomipramine, sulfasalazine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.clopidogrelclopidogrel, sulfasalazine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Clopidogrel and NSAIDs both inhibit platelet aggregation.cordycepssulfasalazine and cordyceps both increase anticoagulation. Use Caution/Monitor.cortisonesulfasalazine, cortisone. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.cyclopenthiazidesulfasalazine increases and cyclopenthiazide decreases serum potassium.